HOLD ON TO

WHAT MOVES YOU
WHAT
MOVES YOU

Learn about NEXVIAZYME, monotherapy* for people with LOPD

*Not including premedication or pretreatment.

LEARN MORE NOW

Small changes matter

Living with LOPD can take away your ability to move your muscles. The impact can be subtle or adjusted to over time. Or you get used to working around them. This self- assessment will help you have a better conversation with your doctor.

TAKE THE
SELF-ASSESSMENT

See a real
NEX step

NEXVIAZYME has made a difference for some LOPD patients, whether they’re newly diagnosed or have switched from another LOPD treatment. Watch this real story.

WATCH VIDEO NOW
TAKE THE SELF‑ASSESSMENT

WHAT'S
YOUR
NEX
MOVE?

Circle image
Not real patients
If you are newly diagnosed

If you’re newly
diagnosed

Your head is probably swirling with questions. We can help answer them. Learn about Pompe, see what the road ahead may look like, and find support at CareConnectPSS®.

LEARN ABOUT POMPE
Curious about NEXVIAZYME?

Curious about NEXVIAZYME?

NEXVIAZYME is an enzyme replacement monotherapy* that’s proven to help people with LOPD breathe easier and walk further. Learn how it works and why it could be worth switching to.

*Not including pretreatment.

LEARN MORE HERE
Already on NEXVIAZYME?

Already on
NEXVIAZYME?

When you live with Pompe, you need more than medicine. CareConnectPSS® can offer clear information, financial assistance for eligible patients, and a caring ally to Pompe patients.

GET TRUSTED
SUPPORT

IMPORTANT SAFETY INFORMATION AND INDICATION

IMPORTANT SAFETY INFORMATION

WARNING: SEVERE HYPERSENSITIVITY REACTIONS, INFUSION-ASSOCIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS

Hypersensitivity Reactions Including Anaphylaxis

If you are taking NEXVIAZYME, you should know that severe and potentially life threatening allergic-type reactions known as anaphylaxis and severe hypersensitivity reactions have occurred during and after NEXVIAZYME treatment. You should seek immediate medical care if signs and symptoms of anaphylaxis or hypersensitivity reactions occur. If such a reaction is severe enough, your doctor may decide to immediately discontinue the infusion and provide immediate medical care. Appropriate medical support measures may be administered during your infusion, and you may require close observation during and after NEXVIAZYME administration.

Infusion-Associated Reactions (IARs)

If you are taking NEXVIAZYME, you should know that severe IARs have occurred during and after NEXVIAZYME treatment. If severe IARs occur during your NEXVIAZYME infusion, your doctor may decide to immediately discontinue the infusion and provide appropriate medical care. If you have an acute underlying illness at the time of NEXVIAZYME infusion you may be at greater risk for IARs. If you have advanced Pompe disease you may have compromised heart and breathing function, which may put you at a higher risk of severe complications from IARs.

Risk of Acute Cardiorespiratory Failure in Susceptible Patients

If you are likely to develop fluid volume overload, or have acute underlying breathing problems or compromised heart or breathing function that may require fluid restriction, there may be a risk of worsening of your heart or breathing status during NEXVIAZYME infusion. Your doctor may decide that close observation during NEXVIAZYME administration may be necessary.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions Including Anaphylaxis: See Boxed WARNING. Your doctor may decide to give you antihistamine, anti-fever and/or steroid medications before your infusions. Your doctor should consider the risks and benefits of restarting the infusion if you have a severe hypersensitivity reaction (including anaphylaxis) to NEXVIAZYME. If a mild or moderate hypersensitivity reaction occurs, your healthcare provider may slow the infusion rate or temporarily stop the infusion.

Infusion-Associated Reactions (IARs): See Boxed WARNING. Your doctor may decide to give you medications before your infusions to decrease the risk of IARs; however, IARs may still occur after receiving these medications. If mild or moderate IARs occur, your healthcare provider should consider decreasing the infusion rate or temporarily stopping the infusion which may help improve the symptoms.

Risk of Acute Cardiorespiratory Failure in Susceptible Patients: See Boxed WARNING.

ADVERSE REACTIONS

The most common adverse reactions (>5%) were headache, fatigue, diarrhea, nausea, joint pain, dizziness, muscle pain, itching, vomiting, shortness of breath, rash, “pins-and-needles” sensation, and hives.

Please see full Prescribing Information for complete details, including Boxed WARNING.

INDICATION

NEXVIAZYME (avalglucosidase alfa-ngpt) is used for the treatment of patients 1 year of age and older with late-onset Pompe disease [lysosomal acid alpha-glucosidase (GAA) deficiency].